Difference between revisions of "Lung carcinoma with ALK rearrangement"

Jump to navigation Jump to search
(tweak)
Line 3: Line 3:
==General==
==General==
*Approximately 1-5% non-small cell lung carcinoma.<ref name=pmid21753699>{{Cite journal  | last1 = Yoshida | first1 = A. | last2 = Tsuta | first2 = K. | last3 = Nakamura | first3 = H. | last4 = Kohno | first4 = T. | last5 = Takahashi | first5 = F. | last6 = Asamura | first6 = H. | last7 = Sekine | first7 = I. | last8 = Fukayama | first8 = M. | last9 = Shibata | first9 = T. | title = Comprehensive histologic analysis of ALK-rearranged lung carcinomas. | journal = Am J Surg Pathol | volume = 35 | issue = 8 | pages = 1226-34 | month = Aug | year = 2011 | doi = 10.1097/PAS.0b013e3182233e06 | PMID = 21753699 }}</ref>
*Approximately 1-5% non-small cell lung carcinoma.<ref name=pmid21753699>{{Cite journal  | last1 = Yoshida | first1 = A. | last2 = Tsuta | first2 = K. | last3 = Nakamura | first3 = H. | last4 = Kohno | first4 = T. | last5 = Takahashi | first5 = F. | last6 = Asamura | first6 = H. | last7 = Sekine | first7 = I. | last8 = Fukayama | first8 = M. | last9 = Shibata | first9 = T. | title = Comprehensive histologic analysis of ALK-rearranged lung carcinomas. | journal = Am J Surg Pathol | volume = 35 | issue = 8 | pages = 1226-34 | month = Aug | year = 2011 | doi = 10.1097/PAS.0b013e3182233e06 | PMID = 21753699 }}</ref>
**Can be treated with ''crizotinib''.<ref name=pmid21475126>{{Cite journal  | last1 = Crystal | first1 = AS. | last2 = Shaw | first2 = AT. | title = New targets in advanced NSCLC: EML4-ALK. | journal = Clin Adv Hematol Oncol | volume = 9 | issue = 3 | pages = 207-14 | month = Mar | year = 2011 | doi =  | PMID = 21475126 }}</ref>


==Microscopic==
==Microscopic==
48,830

edits

Navigation menu